Summary of Key Points from the Conference Call Industry or Company Involved - The conference call focuses on the **2026 Feng Shui Index** and its implications for various industries, particularly the **real estate sector** and the **Hang Seng Index (HSI)**. Core Insights and Arguments - The **2025 market performance** was characterized by volatility, with the Hang Seng Index experiencing unexpected declines and subsequent rebounds, ultimately surpassing initial predictions [4][5]. - The **2026 Feng Shui Index** suggests a positive outlook for the year, with expectations of a strong market performance akin to a galloping horse, indicating a year of opportunities and potential surprises [8][12]. - The **real estate sector** is forecasted to face challenges, as it lacks direct auspicious influences in the current year's predictions. However, specific directions (East and Southeast) are noted to have favorable prospects, while the North and South may encounter disruptions [11][59]. - The **HSI**, categorized as an Earth element, is expected to benefit from the fire energy of the year, leading to a brighter outlook despite previous caution [11][12]. Other Important but Possibly Overlooked Content - The **Feng Shui Index** integrates traditional Chinese metaphysics, including the Five Elements theory, to predict market trends and sector performances [39][46]. - The **Wood element** is expected to thrive in 2026, positively impacting industries related to agriculture, furniture, and pharmaceuticals, while the **Fire element** is anticipated to boost sectors like energy production and communications [42][46]. - The **Water element** is predicted to be weak, potentially hindering the shipping and trade industries, as well as sectors related to small goods and aquaculture [56]. - The **real estate sector** is expected to struggle, but construction materials like sand and cement may see growth, particularly towards the end of the year [49]. This summary encapsulates the essential insights from the conference call, highlighting the anticipated trends and challenges across various sectors as influenced by the Feng Shui Index for 2026.

Summary of the Conference Call for Fosun International Industry and Company Overview - **Company**: Fosun International - **Industry**: Diversified Holdings including healthcare, consumer products, tourism, and insurance Key Points and Arguments 1. **Strategic Focus**: Fosun International is implementing a "slimming down" strategy aimed at systematically enhancing profitability, cash flow generation, and balance sheet health over the next five years, with a gradual increase in shareholder dividends currently maintained at around 20% [2][3][4] 2. **Core Subsidiaries**: The four core subsidiaries of Fosun International are: - **Fosun Health**: Rapid growth in innovative drug revenues with multiple products showing significant potential - **Yuyuan**: Strengthened profitability in fashion jewelry and potential recovery in the liquor business due to consumer recovery - **Fosun Tourism**: Accelerating global resort network expansion with expected profitability improvements - **Fosun Insurance**: Strong premium income growth, leading market share in Portugal [4][6] 3. **Debt Management**: The company aims to reduce interest-bearing debt from a historical peak of 120 billion RMB to below 60 billion RMB, with a target for public market debt to be below 25% [2][8][10] 4. **International Market Performance**: Fosun Pharma has ten products approved in international markets, with strong sales performance and expected significant growth over the next three years, particularly in innovative products like PD-L1 and ADC [5][6] 5. **Yuyuan's Business Transformation**: Yuyuan is actively transforming its brand image and focusing on younger demographics, with new product lines and marketing strategies to align with current consumer trends [2][8] 6. **Capital Allocation**: The company prioritizes capital allocation towards four main industries: health (Fosun Pharma), consumer (Yuyuan and Fosun Tourism), wealth (Portuguese insurance), and manufacturing (Hainan Mining) [4][10] 7. **Operational Efficiency**: The management emphasizes improving operational efficiency and reducing costs, particularly in response to declining profitability in some Yuyuan segments [10][11] 8. **Future Growth Drivers**: Expected growth from innovative drug commercialization, new village expansions, and high-end tourism models is anticipated to contribute to revenue and profit from 2026 to 2027 [11] Other Important Insights - **Market Expansion**: HR Company's gastric cancer surgery phase 3 registration has been successful, with commercialization in over 30 countries, and the U.S. market approval will follow local clinical approval timelines [7] - **IPO Plans**: Fosun Pharma is initiating A-share IPO guidance, which may enhance the valuation of its assets and the overall group [9] - **Collaboration with Clavis Bio**: Fosun Pharma's collaboration involves shared development responsibilities, with specific details to be disclosed publicly [9] This summary encapsulates the essential insights from the conference call, highlighting the strategic direction, financial health, and growth prospects of Fosun International and its subsidiaries.

Market Overview - The Hong Kong stock market opened lower on February 5, with the Hang Seng Index down 219.37 points, a decline of 0.82%, closing at 26,627.95 points [1] - The Hang Seng Tech Index fell by 70.55 points, down 1.31%, to 5,295.89 points [1] - The China Enterprises Index decreased by 69.92 points, a drop of 0.77%, to 8,978.46 points [1] - The Red Chip Index declined by 8.89 points, down 0.2%, to 4,363.4 points [1] - The previous day saw mixed performance among the three major indices, with the Hang Seng Index closing in the green while the Hang Seng Tech Index experienced a drop of over 2% at one point [1] Company Performance - Xinda Biologics (01801.HK) reported a projected total product revenue of approximately RMB 11.9 billion for 2025, reflecting a year-on-year growth of about 45% [2] - Lee & Man Paper Manufacturing (02314.HK) anticipates a profit of approximately HKD 1.88 billion to HKD 2.00 billion for 2025, representing a year-on-year increase of 38% to 47% [2] - ZTO Express (02057.HK) expects total revenue for 2025 to be between RMB 48.5 billion and RMB 50 billion, with a year-on-year growth of about 9.5% to 12.9% due to increased parcel volume [2] - China Resources Cement (01313.HK) forecasts a year-on-year profit increase of approximately 115% to 135% for 2025, driven by cost reductions and decreased impairment losses [2] - Gemdale Corporation (00535.HK) reported a total contract sales amount of approximately RMB 239 million in January, a year-on-year decrease of 61.82% [3] - Fosun International (00656.HK) plans to subscribe to additional registered capital of Shangan Technology for RMB 105 million, acquiring a 51.0879% stake post-capital increase [3] - Shanghai Pharmaceuticals (02607.HK) intends to transfer its 30% stake in Amgen for a minimum listing price of approximately RMB 1.023 billion [3] Corporate Actions - Caocao Travel (02643.HK) completed a placement of 12 million shares at HKD 32.46 per share, raising approximately HKD 383 million [4] - Kingsoft (03888.HK) repurchased 1.0886 million shares for HKD 29.99 million, with repurchase prices ranging from HKD 27.18 to HKD 28 [5] - Xiaomi Group (01810.HK) spent HKD 146 million to repurchase 4.3 million shares at prices between HKD 33.94 and HKD 34.02 [6] - Kingdee International (00268.HK) repurchased 1 million shares for HKD 11.0597 million, with prices between HKD 11.05 and HKD 11.1 [7] Industry Insights - Guosen Securities remains optimistic about the spring market, suggesting a focus on performance-based investments despite potential negative impacts from the rebound of the US dollar index and rising US Treasury yields [8] - CICC noted advancements in global large model technology capabilities, particularly in reasoning and programming, while highlighting ongoing limitations in general capabilities [9] - Xinda Securities pointed out the continuous improvement of regulations in the domestic intelligent connected vehicle sector, with an expected market size of RMB 270 billion for Robo-taxis by 2030 and a projected increase in the logistics vehicle industry value to RMB 594.8 billion by 2030 [9]

Industry News - The Ministry of Culture and Tourism announced the resumption of travel for Shanghai residents to Kinmen and Matsu to normalize cross-strait exchanges and benefit both sides [26] - Reports indicate that Musk's team has been exploring the Chinese photovoltaic industry chain, with orders signed with heterojunction equipment manufacturers [26][17] - The National Medical Insurance Administration issued a notice to strengthen management of designated medical institutions for mental illnesses and combat illegal use of medical insurance funds [26] - The 16th General Assembly of the China Artificial Intelligence Industry Development Alliance was held, focusing on breakthroughs in key technologies such as computing power chips and industrial models [26] - The Guangdong Province issued opinions to accelerate the high-quality construction of a digital society, expanding the operational area for autonomous public transport and smart transportation services [27] - An expert seminar on the "14th Five-Year" development plan for the gold industry emphasized the need to focus on key technological bottlenecks and enhance the integration of production, education, and research [27] - The China Electronics Technology Group announced the successful delivery of the first domestically produced 12-inch silicon carbide wafer thinning equipment, marking a breakthrough in large-size silicon carbide processing [27][28] Company News - JinkoSolar announced that it has not engaged in any cooperation with Musk's team [30] - The Shanghai Stock Exchange issued a regulatory warning to Woge Optoelectronics for inaccurate and incomplete information related to "commercial space" and "brain-computer interface," which may mislead investors [31] - The company Guo Sheng Technology stated that it is not involved in the space photovoltaic business [39] - Jingsheng Mechanical and Electrical announced that the application scenarios for "space photovoltaic" are still in the exploratory stage [39] - Tiantong Co., Ltd. stated that it does not produce commercial satellites or optical module products [39] - Shuangliang Energy announced that it has not yet engaged in space photovoltaic-related business [39] - Chang'an Automobile plans to repurchase company shares worth between 1 billion to 2 billion yuan [48]

昨晚一堆人问 怎么道琼斯和纳斯达克那么分离？ 道琼斯里面都是些啥？苹果，汽车，医药，基建老登！估值低，位置低！ | ( G | | | 美元指数 | | | | | --- | --- | --- | --- | --- | --- | --- | | | | | USDX.FX | | | | | 97.6394 | | 前收 | 97.6302 | | 97.6329 | | | +0.0092 | +0.01% | 卖出 | 97.6394 | 买入 | 97.6394 | | | 最高 | 97.6617 | 今年来 | -0.64% | 20日 | -1.12% | | | 最低 | 97.6187 | 10日 | -1.14% | 60日 | -1.85% | | | 分时 | 五日 | 日K | ョK | EK | 明名 | | | 设均线 产加 | | | MA5:97.4770↑ 10:97.0230↓ 20:97.9931↓ 30:91 切走势线 | | | | | 100.21737 | | | | | | | | 97.6870 | | | | | | | | >> | 16 | | ...

•欧委会对中国风电企业启动深入调查， 商务部发声 •诱导用户高频分享， 微信对元宝违规链接进行限制 1 、 国家主席习近平同美国总统特朗普通电话。 习近平指出，美方有美方的关切，中方有中方的关切。中方言必信，行必果，说到做 到。只要双方秉持平等、尊重、互惠的态度相向而行，就可以找到解决彼此关切的办法。习近平强调，台湾问题是中美关系中最重要的 问题。台湾是中国的领土，中方必须捍卫国家主权和领土完整，永远不可能让台湾分裂出去。美方务必慎重处理对台军售问题。 2 、 市场传闻马斯克团队近期秘密走访多家中国光伏企业，并重点考察了有异质结、钙钛矿技术路线的光伏企业。 对此，协鑫集团、晶 科能源、 TCL 中环、高测股份证实有过接洽。受此消息影响， A 股光伏概念股集体爆发，晶科能源、泽润新能等十多只股票涨停。晶 科能源、高测股份盘后发布公告称，未与相关团队开展任何合作。晶盛机电、双良节能也提示"太空光伏"投资风险。中国光伏行业协会 指出，太空光伏技术仍处早期探索阶段，产业化尚不成熟。 3 、 谷歌母公司 Alphabet2025 年第四季度营收数据超预期， 2026 年资本支出预计为 1750 亿至 1850 亿美元， ...

沈卫民建议，破解儿童用药难题需打出"组合拳"，构建全链条系统性解决方案：强化顶层设计与保障激 励，设立儿童药物研发专项基金，在省内医药产业集聚区布局研发机构，优化注册审批路径，对首仿或 创新儿童药给予6—12个月额外市场独占期，开通境外已上市急需儿童药特别审批通道；加大产业扶持 力度，提高儿童药研发费用加计扣除比例，将其纳入集采单独分组避免"唯低价"中标，改革定价与医保 支付机制，建立国家级儿童临床试验协同网络；强制推行儿童药安全包装与专用量具，从物理上减少家 庭误服、过量服用的风险，开展全民科普行动提升用药认知。 "儿童用药难题是关系国家未来的大事，也是困扰亿万家庭的急事。各方面都动员起来，就一定能让孩 子们能用上'量身定制'的安全好药。"沈卫民说。 在儿科用药方面，"儿童不是成人的缩影"已逐步成为全球共识。"治疗没有专用的儿童剂型，意味着孩 子不得不服用成人药物，这背后潜藏着诸多风险。"交汇点新闻客户端"我请代表委员捎句话"栏目里， 不少家长对于儿童用药"剂量靠猜、用药靠掰"的现象表达了忧虑。 "儿童用药短缺难题是长期存在的系统性顽疾，其根源在于研发、审批、生产、支付全链条中存在多重 堵点。"省政协委员， ...

Core Viewpoint - The article discusses the recent performance of the A-share and Hong Kong stock markets, highlighting the strength of dividend and value styles, while noting the volatility and shifts in market trends over the past months [1][3][5][6][7][8]. Market Performance - The A-share market opened lower but rebounded to close positively, returning to a rating of 3.8 stars [1]. - The overall market showed strength, with large-cap stocks rising significantly while small-cap stocks experienced minor gains [4]. - The dividend and value styles were particularly strong today, with the Shanghai Dividend Index rising by 3% [5][6]. - The A-share market has seen a 50-60% increase since September 2024, with notable surges occurring in three distinct phases [18][20][22]. Market Trends - The first phase of the market surge occurred in the last two weeks of September 2024, with a rise of over 40%, marking the fastest increase in the last decade [20]. - The second phase saw significant growth in the growth style during the third quarter of 2025, with the ChiNext Index achieving a 50% increase in a single quarter [22][23]. - The third phase involved a rally in mid-cap stocks from December 2025 to January 2026, with the CSI 2000 and CSI 1000 indices reaching overvalued levels [26][27]. - Overall, the significant gains in the A-share market were concentrated in approximately 7% of trading days, which contributed to the majority of market returns [28][30]. Investment Philosophy - During periods of market volatility, investors may find it challenging to manage their emotions. The article emphasizes a value investment approach, suggesting that buying stocks equates to purchasing a company [32]. - The concept of holding a fund is likened to owning a "mini conglomerate," which generates profits without requiring active management from the investor [34][36]. - The article encourages investors to adopt a long-term perspective, particularly during bear markets, and to focus on companies that continue to operate and generate profits [40]. New Publication - A new book titled "Dividend Index Fund Investment Guide" has been released, which aims to help investors better understand dividend index funds, a rapidly growing category in recent years [41].

| 股份代號: | 02196 | | --- | --- | | 上市法國名稱: | 上海復星醫藥（集團）股份有限公司 - H股 | | 日期 (日 / 月 / 年): | 04/01/2026 - 04/02/2026 | | 表格序號 | 大股東/董事/最高行政人員名 作出披露的 買入 / 賣出或涉及的 每股的平均價 | | | | | 持有權益的股份數目 佔已發行的 有關事件的日期 | | | --- | --- | --- | --- | --- | --- | --- | --- | | | | 原因 | 股份數目 | | | (請參閱上述*註 | 有投票權股 (日 / 月 / 年) 有 | | | | | | | | | 份百分比 | | | | | | | | | ( 96 ) | | CS20260203E00525 | BlackRock, Inc. | 1001(L) | | 1,013,500(L) | HKD 20.8511 | 28.471.592(L) | 5.16(L)29/01/2026 | | | | | | | | 95.000(S) | 0.02(S) | 格隆汇2月4 ...

医药 2026 年 02 月 04 日 诺诚健华(688428.SH) 商业化放量与对外合作并进，双轮驱动迈向2.0发展阶段 推荐（维持） 股价：21.51 元 主要数据 | 行业 | 医药 | | --- | --- | | 公司网址 | www.innocarepharma.com | | 大股东/持股 | HKSCC NOMINEES LIMITED/51% | | 总股本(百万股) | 1,765 | | 流通 A 股(百万股) | 268 | | 流通 B/H 股(百万股) | 1,496 | | 总市值（亿元） | 209 | | 流通 A 股市值(亿元) | 58 | | 每股净资产(元) | 3.78 | | 资产负债率(%) | 29.9 | 行情走势图 相关研究报告 【平安证券】诺诚健华（688428.SH）*首次覆盖报告* 始于创新、强于执行力，血液瘤及自免领域管线双开花 *推荐20240321 【平安证券】诺诚健华（688428.SH）*半年报点评*奥 布替尼2024上半年快速放量，血液瘤、自免、实体瘤 在研管线稳步推进*推荐20240821 【平安证券】诺诚健华（688428.SH） ...